Lap2alpha expression is controlled by E2F and deregulated in various human tumors.

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• The retinoblastoma (pRB) tumor suppressor pathway is crucial in preventing cancer.
• Dysregulation of pRB and E2F transcription factors is common in human cancers.
• Identifying downstream targets of pRB is essential for understanding tumor suppression.

Purpose of the Study:

• To identify downstream mediators of the pRB tumor suppressor pathway.
• To investigate the role of lamina-associated polypeptide 2 (LAP2) in cancer.
• To determine the regulatory relationship between E2F transcription factors and LAP2 expression.

Main Methods:

• Microarray-based expression analysis to identify potential pRB-regulated genes.
• Chromatin immunoprecipitation (ChIP) assays to confirm E2F binding to the LAP2 promoter.
• Reporter assays with mutated E2F binding sites to assess promoter transactivation.
• Tissue microarray analysis of human tumors to evaluate LAP2alpha expression levels.

Main Results:

• Expression of lamina-associated polypeptide 2 (LAP2) is directly controlled by E2F transcription factors.
• Endogenous E2F binds to the LAP2 promoter in vivo.
• Ectopically expressed E2F transactivates the LAP2 promoter, an effect abolished by mutating E2F binding sites.
• LAP2alpha is overexpressed in a significant percentage of larynx, lung, stomach, breast, and colon cancers.
• LAP2alpha overexpression in tumors correlates with increased tumor proliferation rates.

Conclusions:

• LAP2 is a direct transcriptional target of E2F transcription factors.
• Overexpression of LAP2alpha is a frequent event in various human cancers.
• LAP2alpha may function as a downstream mediator in the pRB/E2F pathway and contribute to tumor proliferation.